List of Excipients in Branded Drug ATIVAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ATIVAN	lorazepam	0187-0063	CELLULOSE, MICROCRYSTALLINE
Bausch Health US LLC	ATIVAN	lorazepam	0187-0063	LACTOSE MONOHYDRATE
Bausch Health US LLC	ATIVAN	lorazepam	0187-0063	MAGNESIUM STEARATE

Ativan Excipient Strategy and Commercial Opportunities for Lorazepam

Last updated: August 6, 2026

Ativan’s active pharmaceutical ingredient, lorazepam, is an old, genericized benzodiazepine with limited molecule-level exclusivity. Commercial value is concentrated in differentiated dosage forms, excipient risk reduction, hospital-ready presentations, adherence products, and lifecycle formulations. The strongest opportunities are alcohol-free parenteral products, low-irritant liquid formulations, orally disintegrating or buccal systems, and packaging that improves stability and controlled-substance handling.

What is the current FDA and commercial status of Ativan?

Ativan is the brand name for lorazepam, a benzodiazepine approved for anxiety disorders, short-term relief of anxiety symptoms, and status epilepticus in injectable presentations. Lorazepam is a Schedule IV controlled substance in the United States. FDA-approved dosage forms include tablets, oral concentrate, and injection [1, 2].

Product	Active ingredient	Principal route	Commercial status
Ativan tablets	Lorazepam	Oral	Brand and generic products
Ativan oral concentrate	Lorazepam	Oral	Brand and generic liquid opportunities
Ativan injection	Lorazepam	Intravenous or intramuscular	Hospital and emergency-use product
Generic lorazepam tablets	Lorazepam	Oral	Multiple ANDA-approved products
Generic lorazepam injection	Lorazepam	Intravenous or intramuscular	Multiple suppliers and contract manufacturers

The original lorazepam compound and early Ativan formulations are no longer meaningful barriers to generic entry. The FDA Orange Book is the controlling source for current reference-listed drug status, patent listings, and regulatory exclusivity [3]. Commercial competition is therefore determined primarily by manufacturing economics, supply reliability, hospital contracts, dosage-form differentiation, and formulation patents rather than by basic API exclusivity.

What excipients are used in Ativan tablets?

Ativan tablets use conventional solid-dose excipients that support direct compression, tablet integrity, disintegration, lubrication, and manufacturability. FDA labeling identifies lactose, microcrystalline cellulose, polacrilin potassium, and magnesium stearate among the inactive ingredients used in lorazepam tablet products [1].

Excipient	Likely functional role	Strategic assessment
Lactose	Diluent and compression aid	Creates a lactose-free positioning opportunity
Microcrystalline cellulose	Filler, binder, disintegration support	Widely available and low IP risk
Polacrilin potassium	Superdisintegrant and ion-exchange excipient	Supports rapid tablet breakup
Magnesium stearate	Lubricant	Standard excipient with potential dissolution tradeoffs

The conventional tablet formulation has a low barrier to replication. A generic manufacturer can generally develop a bioequivalent immediate-release tablet using common excipients, provided it satisfies FDA quality, dissolution, stability, and bioequivalence requirements.

Which tablet excipient opportunities are commercially relevant?

The most credible opportunities are not based on replacing every existing excipient. They involve solving specific clinical, manufacturing, or procurement problems.

A lactose-free tablet could address patients with lactose intolerance, excipient avoidance preferences, or institutional formulary requirements. The commercial opportunity is likely niche because the lactose content in a small lorazepam tablet is low and lactose intolerance does not automatically create a medical need for lactose-free therapy.

A low-magnesium-stearate or alternative-lubricant formulation could improve dissolution robustness. This is more relevant to manufacturing than to patient demand. A developer could use sodium stearyl fumarate, stearic acid, or another compendial lubricant, but any change would require comparative dissolution and stability work.

A directly compressible, low-weight tablet could reduce manufacturing cost and improve content uniformity at the 0.5 mg and 1 mg strengths. Low-dose content uniformity is a technical issue because the API quantity is small relative to tablet mass.

An orally disintegrating tablet could create more commercial differentiation. It may improve administration for patients who have difficulty swallowing, but it must avoid rapid uncontrolled release or excessive bitter taste. Taste masking, moisture protection, tablet friability, and packaging would be central development issues.

What excipients are used in Ativan injection?

Ativan injection uses a solvent system that includes polyethylene glycol 400, propylene glycol, and alcohol. The formulation is supplied in concentrations commonly identified as 2 mg/mL and 4 mg/mL [2]. The label describes excipients used to solubilize lorazepam and support injectable administration.

Excipient	Function in injectable formulation	Key risk
Polyethylene glycol 400	Solubilizer and cosolvent	Viscosity, tolerability, renal handling considerations
Propylene glycol	Cosolvent	Potential toxicity with repeated or high-dose exposure
Alcohol	Cosolvent	Pain, tolerability, pediatric and critical-care concerns
Water for injection	Vehicle	Sterility and endotoxin control

Propylene glycol toxicity is a recognized concern with prolonged or high-dose intravenous administration of drugs formulated with substantial quantities of the solvent. Risk may be higher in neonates, children, patients with renal impairment, and critically ill patients. Alcohol exposure can also limit the attractiveness of the formulation for certain hospital populations.

What are the strongest excipient opportunities for Ativan injection?

Can an alcohol-free lorazepam injection compete with Ativan?

Yes. An alcohol-free formulation is one of the clearest lifecycle opportunities. The product could use alternative cosolvent systems, complexation, surfactants, pH control, or a different concentration strategy to maintain lorazepam solubility without ethanol.

The development challenge is substantial. Lorazepam has limited aqueous solubility, and changing the solvent system can affect:

• Precipitation after dilution.
• Compatibility with infusion bags and tubing.
• Adsorption to container surfaces.
• Injection-site tolerability.
• Chemical degradation.
• Particulate formation.
• Syringe and vial extractables.
• Intravenous and intramuscular bioavailability.

A successful alcohol-free product could target emergency departments, intensive-care units, pediatric hospitals, and institutions seeking to reduce solvent exposure. The strongest commercial positioning would be based on measurable reductions in alcohol and propylene glycol exposure rather than on a generic "clean-label" claim.

Can propylene glycol exposure be reduced?

A reduced-propylene-glycol formulation is technically and commercially relevant. A developer could combine lower cosolvent loading with:

• Cyclodextrin complexation.
• pH optimization.
• Nonionic surfactants.
• Mixed-solvent systems.
• Nano- or microstructured delivery systems.
• Higher-concentration presentations that reduce total injection volume.

Each approach introduces new quality risks. Cyclodextrins may create renal or regulatory concerns depending on the derivative and dose. Surfactants can produce hemolysis, hypersensitivity, or container-compatibility issues. Higher concentrations can increase precipitation and injection-site effects.

A hospital buyer is more likely to pay for reduced solvent burden if the product lowers monitoring requirements, reduces compounding steps, or improves use in pediatric and critical-care settings.

Is a ready-to-administer lorazepam product commercially attractive?

A ready-to-administer syringe or premixed vial could compete on workflow rather than pharmacology. Potential benefits include reduced preparation time, lower compounding error risk, less occupational exposure, and better emergency readiness.

The relevant excipient strategy would include a formulation compatible with:

• Prefilled glass or polymer syringes.
• Long-term storage.
• Light protection.
• Terminal sterilization or aseptic processing.
• Emergency-cart temperature excursions.
• Common infusion materials.

Packaging and device claims may be as valuable as formulation claims. A patent estate could cover the concentration, solvent ratio, container, prefilled syringe, storage condition, and administration method.

What formulation patents could protect a new lorazepam product?

The basic Ativan formulation is unlikely to provide meaningful current exclusivity. New intellectual property would need to focus on a specific technical solution.

Patent target	Potential claim scope	Commercial value
Solvent-reduced injection	Defined lorazepam concentration and solvent ratios	High if safety or hospital use improves
Alcohol-free injection	Lorazepam with alternative solubilization system	High in pediatric and critical-care markets
Orally disintegrating tablet	Matrix, disintegration time, taste masking, packaging	Moderate
Buccal or sublingual film	Polymer, permeation enhancer, dose uniformity	Moderate to high if rapid onset is demonstrated
Stable liquid formulation	pH, antioxidant, preservative, container system	Moderate
Ready-to-administer syringe	Formulation plus container and storage conditions	High for institutional procurement
Manufacturing process	Mixing, sterilization, crystallization, or filling parameters	Moderate, with narrower enforcement
Abuse-deterrent formulation	Physical or chemical resistance to tampering	Uncertain, depending on clinical and regulatory value

Formulation patents should use multiple claim layers. A strong filing would include composition claims, concentration ranges, process claims, container-closure claims, and method-of-use claims tied to a defined patient population or administration setting.

A patent that claims only a broad excipient substitution may be vulnerable to obviousness and routine-optimization arguments. The strongest evidence would show unexpected stability, reduced toxicity, improved injection tolerability, lower precipitation, or a clinically relevant administration advantage.

When does Ativan lose exclusivity?

Ativan’s original small-molecule exclusivity has expired. Generic lorazepam products have been marketed for many years, and generic tablet and injectable products are listed through FDA’s ANDA framework [3, 4].

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
Original product patent protection	Expired
Basic lorazepam composition protection	Expired
Generic ANDA competition	Established
New formulation exclusivity	Available only for a qualifying new product
505(b)(2) exclusivity	Potentially available for a differentiated formulation
Orphan exclusivity	Not inherent to Ativan or lorazepam

A new lorazepam formulation could potentially use a 505(b)(2) application if it relies in part on FDA findings for an approved lorazepam product while introducing a new formulation, route, dosage form, or clinical use [5]. Regulatory exclusivity would depend on the product’s approval basis and the clinical or formulation changes accepted by FDA.

What is the Orange Book status of Ativan?

The Orange Book identifies the reference-listed drug and associated approved generic pathways. Current patent and exclusivity information must be evaluated against the specific NDA and dosage form because tablet, concentrate, and injection products can have different regulatory records [3].

For a new generic tablet or injection, the main legal risk is typically not an Ativan molecule patent. The relevant issues are:

• Whether the selected reference product is the correct RLD.
• Whether listed patents remain active.
• Whether any Paragraph IV certification is required.
• Whether the proposed labeling is identical or appropriately carved out.
• Whether the formulation contains excipients that create safety or quality concerns.
• Whether manufacturing capacity can support controlled-substance distribution requirements.

Which companies are challenging or competing with Ativan?

Generic lorazepam competition has historically included large generic manufacturers, specialty injectable suppliers, and hospital-focused pharmaceutical companies. The relevant competitive set can change by dosage form and contract cycle.

Competitive group	Primary advantage
Large generic manufacturers	Scale, low-cost tablets, broad distribution
Specialty injectable companies	Sterile manufacturing and hospital contracts
Contract manufacturers	Flexible production and private-label supply
Branded-generic suppliers	Packaging, channel access, and controlled-substance logistics
Formulation innovators	Differentiated delivery systems or reduced excipient burden

For tablets, price and availability dominate. For injection, supply continuity, sterile-filling capacity, vial configuration, and hospital purchasing agreements have greater importance. A differentiated injectable product does not need to replace all generic lorazepam volume to succeed. It can target solvent-sensitive populations and institutions with specific procurement criteria.

What Paragraph IV and litigation risks apply to a new lorazepam formulation?

A conventional ANDA applicant may face Paragraph IV issues only if the selected reference product has an unexpired Orange Book patent. For an old lorazepam product, the more probable legal risk is a patent dispute over a new formulation or device owned by a later innovator.

Potential litigation theories include:

• Infringement of a solvent-ratio claim.
• Infringement of an oral-film polymer system.
• Infringement of a prefilled-syringe or container claim.
• Induced infringement based on labeled administration.
• Invalidity for obviousness or lack of written description.
• Non-infringement based on a different excipient or concentration range.

A formulation developer should separate the reference product from the new product. FDA approval does not create freedom to operate, and a non-infringing ANDA formulation may still require a Paragraph IV certification if an unexpired listed patent covers the reference product.

How strong is the patent estate for Ativan?

The legacy Ativan patent estate is weak as a barrier to ordinary generic entry because the active ingredient, core indications, and established dosage forms are mature. A new excipient-based estate could be stronger if it solves a well-defined injectable or administration problem.

Estate characteristic	Assessment
API patent barrier	Low
Basic tablet formulation barrier	Low
Conventional liquid formulation barrier	Low to moderate
Solvent-reduced injection	Moderate to high if technically differentiated
Ready-to-administer presentation	Moderate
Buccal or film product	Moderate, subject to clinical proof
Manufacturing process	Moderate but potentially narrow
Geographic enforceability	Dependent on country-specific filings and prosecution

The most defensible patents would combine formulation and product configuration. For example, a patent covering lorazepam at a defined concentration, a specific cosolvent profile, a container material, and a stability period is more difficult to design around than a claim covering only the use of polyethylene glycol.

What generic launch scenarios exist for lorazepam?

Low-cost conventional generic

This is the most likely and lowest-risk pathway. A manufacturer uses established excipients, develops an immediate-release tablet or conventional injection, and competes on price and supply reliability. Margins are likely constrained by multiple suppliers.

Premium hospital injection

A manufacturer launches an alcohol-free, reduced-propylene-glycol, ready-to-administer, or lower-volume product. The commercial case depends on hospital pharmacy economics and clinical acceptance.

Patient-centered oral dosage form

An orally disintegrating tablet, oral film, or low-volume liquid targets swallowing difficulty, adherence, or administration in supervised settings. This pathway requires stronger taste-masking and human-use data.

Licensed or partnered platform

A specialty pharmaceutical company licenses a solubilization technology, film platform, or prefilled-syringe system and applies it to lorazepam. The deal value would depend on whether the platform can support multiple controlled substances or emergency medicines.

How does Ativan compare with other benzodiazepines?

Product	Active ingredient	Common differentiation issue	Excipient opportunity
Ativan	Lorazepam	Injectable solvent burden and controlled-substance handling	Alcohol-free injection, ready-to-administer formats
Valium	Diazepam	Poor aqueous solubility and injectable formulation complexity	Alternative solubilization and reduced-irritant systems
Versed	Midazolam	Injectable and intranasal delivery	Fast administration and device-based delivery
Xanax	Alprazolam	High-volume oral generic competition	ODT, taste masking, abuse-deterrent concepts
Klonopin	Clonazepam	Oral dosage-form differentiation	ODT and liquid administration

Lorazepam has a practical advantage for lifecycle development because injectable use creates a clearer solvent and hospital-workflow problem than many oral benzodiazepine products. The market is constrained, however, by controlled-substance regulation, safety warnings, and the availability of low-cost generic tablets.

What FDA regulatory pathway applies to excipient innovation?

A conventional generic with the same dosage form and route would generally use an ANDA, with bioequivalence and pharmaceutical equivalence requirements [4]. A materially different formulation may require a 505(b)(2) application, particularly if it introduces a new route, delivery system, concentration, or clinically meaningful formulation change [5].

Regulatory planning should focus on:

• FDA Inactive Ingredient Database precedent.
• Maximum daily exposure for each excipient.
• Injectable compatibility and particulate controls.
• Preservative justification for multidose products.
• Extractables and leachables.
• Stability under intended storage conditions.
• Dose uniformity at low lorazepam strengths.
• Human-factor validation for prefilled devices.
• Controlled-substance manufacturing and distribution controls.

An excipient that is acceptable in an oral tablet may not be appropriate for intravenous administration. Novel excipient use can increase development time and regulatory review risk.

What manufacturing and IP barriers affect commercialization?

The main manufacturing barrier for tablets is low-dose content uniformity. For liquids and injections, the bottleneck is solubility and sterile processing. A product may have an attractive patent position but fail commercially if it requires expensive aseptic processing, specialized container systems, or low-throughput filling.

Key barriers include:

• Lorazepam segregation during blending.
• Solvent evaporation during liquid processing.
• Precipitation during dilution.
• Glass or polymer adsorption.
• Sterile filtration limitations.
• Container-closure integrity.
• Controlled-substance inventory controls.
• Limited hospital willingness to stock multiple presentations.
• Scale-up changes in particle size and dissolution.

The best commercial target is a formulation with a measurable operational benefit and a manufacturing process that remains compatible with existing sterile or solid-dose infrastructure.

Key Takeaways

• Ativan’s original API and core formulation exclusivity have expired.
• Conventional lorazepam tablets are highly exposed to generic competition.
• The strongest excipient opportunity is a solvent-reduced or alcohol-free injectable formulation.
• Propylene glycol reduction has clinical and procurement relevance, particularly in pediatric and critical-care settings.
• Ready-to-administer syringes can create value through workflow efficiency and reduced preparation risk.
• Orally disintegrating tablets and buccal films offer differentiation but require taste-masking and clinical-use evidence.
• New patent protection should combine excipient composition, concentration, manufacturing process, container, and administration claims.
• An ANDA is generally suitable for conventional generic products; differentiated formulations may require a 505(b)(2) pathway.
• Commercial success depends on hospital contracts, sterile manufacturing capacity, controlled-substance logistics, and demonstrated clinical or operational benefit.

FAQs About Ativan Excipient Strategy

Can lorazepam be formulated without propylene glycol?

Potentially. A replacement system would need to maintain solubility, sterility, stability, dilution compatibility, and acceptable injection tolerability. Cyclodextrins, surfactants, mixed solvents, and pH optimization are possible approaches.

Is an Ativan oral liquid a strong commercial opportunity?

It is a niche opportunity. Demand may come from patients who cannot swallow tablets, but the product must overcome taste, stability, preservative, dosing-device, and controlled-substance handling requirements.

Could an Ativan orally disintegrating tablet receive new exclusivity?

A genuinely new dosage form may support formulation patents and, depending on the development program, regulatory exclusivity. The product would need a defensible technical difference and a qualifying FDA approval pathway.

Are Ativan excipients protected by active patents?

The conventional excipients used in legacy lorazepam products are generally standard pharmaceutical materials. Any current protection would more likely involve a later-developed formulation, delivery device, manufacturing process, or container system.

What is the highest-value licensing opportunity around lorazepam?

A platform that enables alcohol-free, low-propylene-glycol, ready-to-administer injectable lorazepam has the clearest licensing potential. Its value would increase if the same technology applies to diazepam, midazolam, or other poorly water-soluble emergency medicines.

References

1. Pfizer Inc. (2023). Ativan (lorazepam) tablets prescribing information. U.S. Food and Drug Administration.
2. Pfizer Inc. (2023). Ativan (lorazepam) injection prescribing information. U.S. Food and Drug Administration.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA): Generics.
5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
6. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
7. U.S. Drug Enforcement Administration. (2024). Controlled substances schedules.